ExpreS2ion Biotech Holding AB

Equities

EXPRS2

SE0008348262

Pharmaceuticals

Delayed Nasdaq Stockholm 11:29:39 2024-04-23 am EDT 5-day change 1st Jan Change
2.995 SEK +7.73% Intraday chart for ExpreS2ion Biotech Holding AB +10.52% +41.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate CI
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial MT
ExpreS2ion Biotech Unit Secures EUR8 Million Grant for Virus Vaccine Project; Shares Soar MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ExpreS2ion Biotech Holding AB Announces Changes to Leadership Team CI
Expres2ion Biotech Affiliate to Assess Strategic Options for Breast Cancer Project MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Certain Shares of ExpreS2ion Biotech Holding AB are subject to a Lock-Up Agreement Ending on 14-JUL-2023. CI
ExpreS2ion Biotech Holding AB(OM:EXPRS2) dropped from S&P Global BMI Index CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ExpreS2ion Biotech Holding AB Auditor Raises 'Going Concern' Doubt CI
ExpreS2ion Biotech to Issue New Units to Guarantors Under Rights Issue MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
ExpreS2ion Biotech Names Chief Scientific Officer MT
ExpreS2ion Biotech Holding AB Appoints Dr. Farshad Guirakhoo as Chief Scientific Officer, Effective January 16, 2023 CI
Evaxion Biotech Teams Up With ExpreS2ion Biotechnologies for Vaccine Candidate Development MT
ExpreS2ion, Evaxion Team Up to Develop New Cytomegalovirus Vaccine MT
ExpreS2ion and Evaxion Biotech A/S Initiates Research Collaboration on a Novel Cytomegalovirus Vaccine Candidate CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Expres2ion Biotech Holding AB Announces Durable Antibody Response Reported for the Abncov2 Covid-19 Vaccine Six Months After Vaccination in the Phase Ii Clinical Trial CI
ExpreS2ion Biotech Holding AB Announces Resignation of Allan Rosetzsky from the Board of Directors CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Certain Shares of ExpreS2ion Biotech Holding AB are subject to a Lock-Up Agreement Ending on 4-AUG-2022. CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chart ExpreS2ion Biotech Holding AB
More charts
ExpreS2ion Biotech Holding AB is a Sweden-based biopharmaceutical company. The Company specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The Company's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. It also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.995 SEK
Average target price
9 SEK
Spread / Average Target
+200.50%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. EXPRS2 Stock
  4. News ExpreS2ion Biotech Holding AB
  5. ExpreS2ion Up 34% After Releasing Further Data From Booster Vaccine Clinical Trial